Clinical trials: Anlotinib
Non-small Cell Lung Cancer
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules…
- Trial name
- NCT04273815
- Testing
- TQ-A3334, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450 injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary adenocarcinoma/hepatocellular carcinoma
- Trial name
- NCT03825705
- Testing
- TQB2450 injection, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Alveolar Soft Part Sarcoma
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or…
- Trial name
- NCT07548177
- Testing
- Benmelstobart injection combined with Anlotinib hydrochloride capsule
- Where
- 15 sites in China
- Volunteers
- 33 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recurrent Platinum-resistant Ovarian Cancer
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus weekly treatment with paclitaxel of recurrent platinum-resistant ovarian cancer.A total of 405…
- Trial name
- NCT05145218
- Testing
- Anlotinib Hydrochloride Capsules, Paclitaxel injection, TQB2450 injection
- Where
- 2 sites in China
- Volunteers
- 405 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Osteosarcoma, Other Solid Tumors
TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
This is a multicenter, open-label, multi-cohort Phase Ib trial to evaluate the efficacy and safety of TQB2928 injection combined with anlotinib hydrochloride capsule in patients with relapsed/metastatic osteosarcoma and other…
- Trial name
- NCT06438783
- Testing
- 1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib
- Where
- 5 sites in China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.
- Trial name
- ALTER0703 (NCT02332499)
- Testing
- Anlotinib
- Where
- 29 sites in China
- Volunteers
- 419 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Unresectable Metastatic Colorectal Cancer
A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
A clinical study to compare the efficacy and safety of AK105 plus anlotinib and Capecitabine/Oxaliplatin (CapeOx) , anlotinib plus CapeOx, bevacizumab plus CapeOx. A total of 120 cases will be enrolled to the group.
- Trial name
- NCT05068206
- Testing
- AK105 injection, Anlotinib hydrochloride capsule, CapeOX
- Where
- 13 sites in China
- Volunteers
- 120 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Differentiated Thyroid Cancer
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Differentiated Thyroid Cancer.
- Trial name
- NCT02586337
- Testing
- Anlotinib
- Where
- 19 sites in China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
- Trial name
- ALTER0802 (NCT02809534)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- NCT01924195
- Testing
- Anlotinib
- Where
- 13 sites in China
- Volunteers
- 117 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pancreatic Carcinoma
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
This study is divided into three phases: single-dose exploration, combination dosage exploration and cohort expansion. The Single-dose exploration stage aims to evaluate the tolerability of TQB2858 injection in subjects with…
- Trial name
- NCT05193604
- Testing
- TQB2858 injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride for injection
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Medullary Thyroid Carcinoma
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.
- Trial name
- NCT02586350
- Testing
- Anlotinib
- Where
- 19 sites in China
- Volunteers
- 91 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib.
- Trial name
- NCT04344158
- Testing
- AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
- Where
- 81 sites in China
- Volunteers
- 648 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer.
- Trial name
- NCT04574284
- Testing
- TQB2450, Anlotinib
- Where
- 36 sites in China
- Volunteers
- 170 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastroenteropancreatic Neuroendocrine Tumor G3
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.
- Trial name
- NCT03457844
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer, Ovarian Cancer
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD).
- Conditions
- Endometrial Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- AL3818 (NCT02558348)
- Testing
- AL3818
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advenchen Laboratories, LLC
Healthy Volunteer
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.
- Trial name
- NCT07438886
- Testing
- AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Small Cell Lung Cancer Limited Stage
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
This study is a randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell…
- Trial name
- NCT06469879
- Testing
- TQB2450+Anlotinib
- Where
- 16 sites in China
- Volunteers
- 358 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors
Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer patients.
- Trial name
- NCT02622932
- Testing
- Anlotinib and 14C-labeled Anlotinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lung Cancer
Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation positive non-small cell lung cancer.
- Trial name
- NCT03983928
- Testing
- TQB2450, Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.